Skip to main content

Incidence of Uterine Bleeding following Oral Anticoagulant Use in Food and Drug Administration’s Sentinel System

Basic Details
Date
Thursday, November 26, 2020
Type
Publication
Description

To better understand the occurrence of uterine bleeding (UB) events requiring intervention in women treated with oral anticoagulants (OAs), we examined the incidence of UB events in the Food and Drug Administration’s (FDA) Sentinel System.

Materials

Am. J. Obstet. Gynecol. 2020 Nov 26. doi.org/10.1016/j.ajog.2020.11.034

Related Assessment(s)
Incidence of Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Descriptive Analysis
Incidence of Severe Uterine Bleeding Outcomes among Oral Anticoagulant Users and Nonusers
Sentinel Drug Assessment: Eliquis (Apixaban), Pradaxa (Dabigatran), and Xarelto (Rivaroxaban) & Severe Uterine Bleed
Author(s)

Abby Anderson, Audrey Gassman, Laura Hou, Ting-Ying Huang, Efe Eworuke, David Moeny, Hui-Lee Wong

Corresponding Author

Abby Anderson; Division of Urology, Obstetrics, and Gynecology, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
Email: abby.anderson@fda.hhs.gov